Market News & Trends
Bellerophon Therapeutics Selects Flextronics to Manufacture Next-Generation Device
Bellerophon Therapeutics, Inc. recently announced it has selected Flextronics International Ltd. as its manufacturing partner for the INOpulse Mark2, the company’s next-generation pulsatile nitric oxide…
GSK & Cold Spring Harbor Laboratory to Develop Diabetes & Obesity Therapeutic
Cold Spring Harbor Laboratory (CSHL) recently announced a collaboration with GSK to develop a treatment for obesity and type 2 diabetes. Scientists at CSHL and…
CASI Pharmaceuticals Announces Initiation of Phase II Trial With ENMD-2076
CASI Pharmaceuticals, Inc. recently announced that it has initiated a Phase II trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC)…
Capsugel Investing More Than $25 Million in Increased Production Capacity & Quality Enhancements
Capsugel recently announced it is investing more than $25 million to increase production capacity and deliver further quality enhancements for its industry-leading vegetarian capsules. The…
Can-Fite Signs Multi-Million Dollar Distribution Agreement
Can-Fite BioPharma Ltd. recently announced it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment…
Confluence Pharmaceuticals Signs Co-Development & Marketing Agreement
Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals AG recently announced they have signed a definitive agreement to co-develop and market Confluence’s lead asset, a product for the…
Identification of Foreign Particulate Matter Using Automated Raman & Automated SEM-EDS
By: Angela Flowers, Emily Landsperger, Rebekah Byrne, and Dave Exline, Gateway Analytical Foreign particulate matter in drug products is a common problem in the…
Ruthigen & Pulmatrix Enter Into Merger Agreement
Ruthigen, Inc. recently announced it have entered into a definitive merger agreement. Upon the closing of the transactions contemplated by the merger agreement, Pulmatrix will…
Key TxCell Patent to be Granted for its Lead Product
TxCell SA recently announced that a key patent is to be granted by the United States Patent and Trademark Office (USPTO). The issue notification has…
Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation
Immune Pharmaceuticals Inc. recently announced it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of…
Xcelience Receives DEA Approval to Develop & Manufacture DEA Schedule I Drug Products
Xcelience, a CDMO, located in Tampa, FL, is excited to announce that they have received approval from the Federal Drug Enforcement Agency to develop and…
Alizé Pharma III Raises $1.94 Million for Osteoporosis Program
Alizé Pharma III SAS recently announced that it has raised $1.94 million in a first financing round. The funding round was supported by a syndicate…
Cloud Pharmaceuticals & University of Florida Collaborate on Rapid Design of Novel Cancer Inhibitors
Cloud Pharmaceuticals and the University of Florida Department of Medicine recently announced an academic collaboration that will help rapidly design and develop novel drugs to…
Germany’s Pharmaceutical Market Value Will Crawl to $65 Billion
While Germany is the leading pharmaceutical market in Europe, valued at $58.6 billion in 2014, the sector will expand at a modest Compound Annual Growth…
The $700-Billion Connected Life Market That Will Drive Change & Growth
We are living a connected life in a connected world. Our smartphone is our gateway to the world, and very soon, we will be able…
From Volume to Value
By: Alan Shortall, Unilife Chairman & CEO As healthcare markets continue to shift to a model based on value-based outcomes, Bluetooth-enabled smart medical technologies…
New Mechanism for Engineering Genetic Traits Governed by Multiple Genes Paves Way for Various Advances
When it comes to gene expression, scientists have so far studied one single gene at a time. A new approach developed by Harvard geneticist George…
PhaseBio Raises $40 Million, Led By AstraZeneca
PhaseBio Pharmaceuticals, Inc., a leading company in the field of biopolymer-based drugs and focused on developing treatments for metabolic and specialty cardiopulmonary disorders, recently announced…
Charleston Laboratories & Daiichi Sankyo Announce Completion of Pharmacokinetics Study
Charleston Laboratories, Inc. and its co-development and co-commercialization partner, Daiichi Sankyo, Inc., recently announced the completion of a pharmacokinetics study on CL-108, Charleston Laboratories' lead…
Kura Oncology Announces License Agreement; Closes $60 Million
Kura Oncology, Inc. recently announced it has entered into an agreement with Janssen Pharmaceutica NV for an exclusive license to develop and commercialize tipifarnib in…
